Physicians are used to Imbruvica and we do not expect a rapid and massive shift towards Calquence but we do see it progressively taking market share from the leader. Bryan Garnier analysts More Quotes by Bryan Garnier analysts More Quotes From Bryan Garnier analysts On the negative side, with such a disposal, tension on the P&L and therefore on the dividend will come back. Bryan Garnier analysts company-news
